Proton Pump Inhibitor Clinical Trial
Official title:
Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor After 8 Weeks of Treatment in Geriatric Population
| NCT number | NCT03467893 |
| Other study ID # | EGERIPP |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 10, 2017 |
| Est. completion date | February 28, 2018 |
| Verified date | March 2018 |
| Source | Groupe Hospitalier Paris Saint Joseph |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Proton pump inhibitor are frequently used and are short term well tolerated ; but few studies
show there are adverse event in long term prescription like fracture or pulmonary infection
to Clostridum difficile. The fact is that multi medication in old patient increase the
iatrogenic risk and decrease the medication compliance. The Proton pump inhibitor (PPI)are
overused in this patient category.Several studies suggest the existence of a rebound effect
when people were treated more than 8 weeks ; this effect seems to appear around 14 days after
with hyperacidity symptoms.
But there are no studies about old patient. So in this context the aim of the study is to
evaluate the prevalence of rebound effect occurence after the end of PPI 8 weeks treatment.
| Status | Completed |
| Enrollment | 30 |
| Est. completion date | February 28, 2018 |
| Est. primary completion date | July 1, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 65 Years and older |
| Eligibility |
Inclusion Criteria: - patients hospitalized in post acute and rehabilitation service - more than 65 years old - PPI prescription more than 8 weeks Exclusion Criteria: - PPI prescription under 8 weeks - PPI prescription for digestive haemorragy |
| Country | Name | City | State |
|---|---|---|---|
| France | Groupe Hospitalier Paris Saint Joseph | Paris | Ile-de-France |
| Lead Sponsor | Collaborator |
|---|---|
| Groupe Hospitalier Paris Saint Joseph |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of antacids used | Day 14 after end of treatment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03038009 -
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
|
Phase 4 | |
| Completed |
NCT04637750 -
Proton Pump Inhibitors (PPI): a Study to Improve Appropriate Prescriptions in the Elderly
|
N/A | |
| Active, not recruiting |
NCT05647278 -
A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )
|
Phase 4 | |
| Completed |
NCT05348252 -
Patient Journey Application for Discontinuing Inappropriate PPI Use: a Randomized Controlled Trial
|
N/A | |
| Recruiting |
NCT05590286 -
A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT03980899 -
Evaluation of the Long-term Tolerance of Proton Pump Inhibitor (PPI) Discontinuation in Geriatric Patients Treated With Long-term Therapy Without a Recognized Indication
|
||
| Completed |
NCT05533619 -
Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury
|
||
| Completed |
NCT03079050 -
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan
|
Phase 4 | |
| Completed |
NCT02718261 -
Sup-Icu RENal (SIREN)
|
Phase 4 | |
| Completed |
NCT04329000 -
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
|
N/A | |
| Recruiting |
NCT03098537 -
Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial
|
N/A |